The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP CRN Discovery Fellowship 2025, 2026Unravelling the Impact of the Microbiome on Motor Dysfunction in Parkinson’s Disease Using Phenotypic Heterogeneity in the Pink1-/- Infection-Induced Disease Model
Study Rationale:
Development of Parkinson’s Disease (PD) involves genetic and environmental factors. Not all people with genetic risk factors for PD develop the disease...
-
Research Grant, 2026Automated Platform for Standardizing and Validating GBA1 Human iPSC Models To Accelerate Mechanistic and Therapeutic Discovery in Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene are the most common known genetic risk factors for Parkinson’s disease (PD). Individuals who carry these mutations not only have an increased risk of...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026PWR-PD (“Power-PD”): Personalized Wearable-based Rehabilitation for Parkinson’s Disease
Study Rationale:
Gait impairments are common among people with Parkinson’s disease (PD), leading to an increased fall risk and a reduced quality of life. More and more people are...
-
Spring 2022 RFA: Parkinson’s Pathway Molecular Data Analysis Program, 2026Biomarker Signatures of Parkinson’s Disease Using a Novel Progression Model
Study Rationale:
Parkinson’s disease (PD) affects everyone differently. While no two people are alike in how they experience PD, there are groups of people with PD who share similar...
-
The Bridge Initiative - Supplement: Parkin peptide binders characterization - powder reconfirm and structures, 2026The Bridge Initiative
Study Rationale:
Despite broad efforts to develop pharmacological compounds against important PD targets, such as Parkin and GBA, there is a lack of publicly available chemical...
-
Parkinson’s Disease Therapeutics Pipeline Program - Pre-Clinical, 2026LARKIN
Study Rationale:
Parkinson’s disease is a progressive brain disorder in which dopamine-producing nerve cells gradually die, leading to worsening movement and other symptoms. Research...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.